Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Saldanha said he hasn’t yet fully figured out how to deploy much of the proceeds of the licensing deal, but added that he ...

This was the stock's second consecutive day of losses.

Europe active pharmaceutical ingredients (API) market was valued at $ 49.4 billion in 2022 and will grow by 6.8% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...

North America active pharmaceutical ingredients (API) market is projected to grow by 4.8% annually in the forecast period and reach $120.7 billion by 2032, driven by rising adoption of biologics in ...

The stock's fall snapped a three-day winning streak.

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innovation. It reinforces the notion that India-based ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...